Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low-Risk TAVR Trial Shows Low Mortality at 1 Year

Publish date:: March 9, 2019

Key clinical point: Anticipating pivotal trials due next week at ACC, investigator-led study shows excellent TAVR results in low risk patients.

Major finding: At one year, cardiovascular-related mortality was 1% and there were no disabling strokes.

Data Source: Investigator-led non-randomized study.

Disclosures: Dr. Waksman reports financial relationships with numerous manufacturers of devices for interventional cardiology including those that produce TAVR devices.

Citation:

2019 Cardiovascular Research Technologies.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,